Submissions from 2020
760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab, Yoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, John Cha, Brian D. Piening, Brian Piening, Brendan Curti, Walter Urba, and William L. Redmond
386 Phase I/Ib first-in-human study of HEK-NIZ985, a recombinant IL-15/IL-15Rα heterodimer, alone and in combination with spartalizumab, in adults with advanced and metastatic solid tumors, Rom Leidner, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Douglas McNeel, Kevin Conlon, Nehal Parikh, Jessica O'Keeffe, Niladri Roy Chowdhury, Xiaoli Wang, Ryan Sullivan, and John Thompson
386 Phase I/Ib first-in-human study of HEK-NIZ985, a recombinant IL-15/IL-15Rα heterodimer, alone and in combination with spartalizumab, in adults with advanced and metastatic solid tumors, Rom Leidner, Andrea Wang-Gillam, Sumati Gupta, Robert Wesolowski, Douglas McNeel, Kevin Conlon, Nehal Parikh, Jessica O'Keeffe, Niladri Roy Chowdhury, Xiaoli Wang, Ryan Sullivan, and John Thompson
Metabolic Dynamics and Prediction of Gestational Age and Time to Delivery in Pregnant Women., Liang Liang, Marie-Louise Hee Rasmussen, Brian D. Piening, Xiaotao Shen, Songjie Chen, Hannes Röst, John K Snyder, Robert Tibshirani, Line Skotte, Norman Cy Lee, Kévin Contrepois, Bjarke Feenstra, Hanyah Zackriah, Michael Snyder, and Mads Melbye
CT301 - A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors, Juanita S. Lopez, Ross Camidge, Marco Iafolla, Sylvie Rottey, Martin Schuler, Matthew Hellmann, Ali Balmanoukian, Luc Dirix, Michael Gordon, Ryan Sullivan, Brian S. Henick, Charles Drake, Kit Wong, Patricia LoRusso, Patrick Ott, Lawrence Fong, Aglaia Schiza, Jeffrey Yachnin, Christian Ottensmeier, Fadi Braiteh, Johanna Bendell, Rom Leidner, George Fisher, Guy Jerusalem, Laura Molenaar-Kuijsten, Marcus Schmidt, Scott A. Laurie, Raid Aljumaily, Achim Rittmeyer, Eelke Gort, Ignacio Melero, Lars Mueller, Rachel Sabado, Patrick Twomey, Jack Huang, Manesh Yadav, Jingbin Zhang, Felicitas Mueller, Evelyna Derhovanessian, Ugur Sahin, Ozlem Tureci, and Thomas Powles
Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors, Juanita S. Lopez, Ross Camidge, Marco Iafolla, Sylvie Rottey, Martin Schuler, Matthew Hellmann, Ani Balmanoukian, Luc Dirix, Michael Gordon, Ryan Sullivan, Bryan S. Henick, Chares Drake, Kit Wong, Patricia LoRusso, Patrick Ott, Lawrence Fong, Aglaia Schiza, Jeffrey Yachnin, Christian Ottensmeier, Fadi Braiteh, Joanna Bendell, Rom Leidner, George Fisher, Guy Jerusalem, Laura Molenaar-Kuijsten, Marcus Schmidt, Scott A. Laurie, Raid Aljumaily, Achim Rittmeyer, Eelke Gort, Ignacio Melero, Lars Mueller, Rachel Sabado, Patrick Twomey, Jack Huang, Manesh Yadav, Jingbin Zhang, Felicitas Mueller, Evelyna Derhovanessian, Ugur Sahin, Ozlem Tureci, and Thomas Powels
154 Marrow-infiltrating lymphocytes (MILs): A novel adoptive immunotherapy for hematological and solid tumors, Eric Lutz, Lakshmi Rudraraju, Elizabeth DeOliveira, Amanda Seiz, Monil Shah, Celine Colmenares, Beverly Dan Fu, Daniela Bota, Collin Brummel, Chad Brenner, Paul Swiecicki, Nicole E. Fredich, David B Page, Eleni Efstatihiou, Ivan Borrello, and Kimberly Noonan
154 Marrow-infiltrating lymphocytes (MILs): A novel adoptive immunotherapy for hematological and solid tumors, Eric Lutz, Lakshmi Rudraraju, Elizabeth DeOliveira, Amanda Seiz, Monil Shah, Celine Colmenares, Beverly Dan Fu, Daniela Bota, Collin Brummel, Chad Brenner, Paul Swiecicki, Nicole E. Fredich, David B Page, Eleni Efstatihiou, Ivan Borrello, and Kimberly Noonan
Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC)., Vicky Makker, Matthew H Taylor, Carol Aghajanian, Ana Oaknin, James Mier, Allen Lee Cohn, Margarita Romeo, Raquel Bratos, Marcia S. Brose, Christopher DiSimone, Mark Messing, Lea Dutta, Min Ren, Emmett V. Schmidt, Robert Orlowski, Jodi Alicia McKenzie, Kathryn Gillis, and Antonio Casado Herraez
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer., Vicky Makker, Matthew H Taylor, Carol Aghajanian, Ana Oaknin, James Mier, Allen L Cohn, Margarita Romeo, Raquel Bratos, Marcia S Brose, Christopher DiSimone, Mark Messing, Daniel E Stepan, Corina E Dutcus, Jane Wu, Emmett V Schmidt, Robert Orlowski, Pallavi Sachdev, Robert Shumaker, and Antonio Casado Herraez
PD47-04 SINGLE CELL RNA-SEQUENCING OF FRESH SUPERFICIAL NON-MUSCLE INVASIVE BLADDER CANCER DEMONSTRATES GENE EXPRESSSION PATHWAY DIFFFERENCES BETWEEN HIGH AND LOW GRADE TUMORS, Stanley Malkowiicz, Brian D. Piening, Alexa Dowdell, David Walls, Nik Nair, Baoli Chang, and Brendan Keating
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing, advanced solid tumors., Aaron Scott Mansfield, David S. Hong, Christine L. Hann, Anna F. Farago, Himisha Beltran, Saiama Naheed Waqar, Andrew Eugene Hendifar, Lowell Brian Anthony, Matthew H Taylor, Alan Haruo Bryce, Scott T. Tagawa, Karl D. Lewis, Jiaxin Niu, Christine H. Chung, James M. Cleary, Michael Rossi, Carrianne Ludwig, Ricardo Valenzuela, Yan Luo, and Rahul Raj Aggarwal
Association of immunophenotype with expression of topoisomerase II α and β in adult acute myeloid leukemia., Andrew P Michelson, Shannon McDonough, Cheryl L Willman, Eric R Koegle, John E Godwin, Stephen H Petersdorf, Alan F List, Megan Othus, Frederick R Appelbaum, Jerald P Radich, Mahrukh K Ganapathi, Anjali S Advani, and Ram N Ganapathi
422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts, Mark Middleton, Francesca Aroldi, Joseph Sacco, Mohammed Milhem, Brendan Curti, Ari VanderWalde MBioeth, Scott Baum, Adel Samson, Anna Pavlick, Jason Chesney, Jiaxin Niu, Terence Rhodes, Tawnya Bowles, Robert Conry, Anna Olsson-Brown, Douglas Earl Laux, Howard Kaufman, Praveen Bommareddy, Alex Deterding, Selda Samakoglu, Robert Coffin, and Kevin Harrington
422 An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts, Mark Middleton, Francesca Aroldi, Joseph Sacco, Mohammed Milhem, Brendan Curti, Ari VanderWalder MBioeth, Scott Baum, Adel Samson, Anna Pavlick, Jason Chesney, Jiaxin Niu, Terence Rhodes, Tawnya Bowles, Robert Conry, Anna Olsson-Brown, Douglas Earl Laux, Howard Kaufman, Praveen Bommareddy, Alex Deterding, Selda Samakoglu, Robert Coffin, and Kevin Harrington
An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts., Mark R. Middleton, Francesca Aroldi, Joseph Sacco, Mohammed M. Milhem, Brendan Curti, Ari M. Vanderwalde, Scott Baum, Adel Samson, Anna C. Pavlick, Jason Alan Chesney, Jiaxin Niu, Terence Duane Rhodes, Tawnya Lynn Bowles, Anna Olsson-Brown, Douglas Earl Laux, Praveen Bommareddy, Alex Deterding, Joseph Elassal, Robert S. Coffin, and Kevin Harrington
Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer., Bernhard Mlecnik, Carlo Bifulco, Gabriela Bindea, Florence Marliot, Alessandro Lugli, J Jack Lee, Inti Zlobec, Tilman T Rau, Martin D Berger, Iris D Nagtegaal, Elisa Vink-Börger, Arndt Hartmann, Carol Geppert, Julie Kolwelter, Susanne Merkel, Robert Grützmann, Marc Van den Eynde, Anne Jouret-Mourin, Alex Kartheuser, Daniel Léonard, Christophe Remue, Julia Y Wang, Prashant Bavi, Michael H A Roehrl, Pamela S Ohashi, Linh T Nguyen, SeongJun Han, Heather L MacGregor, Sara Hafezi-Bakhtiari, Bradly G Wouters, Giuseppe V Masucci, Emilia K Andersson, Eva Zavadova, Michal Vocka, Jan Spacek, Lubos Petruzelka, Bohuslav Konopasek, Pavel Dundr, Helena Skalova, Kristyna Nemejcova, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Gennaro Ciliberto, Michele Maio, Luigi Laghi, Fabio Grizzi, Tessa Fredriksen, Bénédicte Buttard, Lucie Lafontaine, Daniela Bruni, Anastasia Lanzi, Carine El Sissy, Nacilla Haicheur, Amos Kirilovsky, Anne Berger, Christine Lagorce, Christopher Paustian, Carmen Ballesteros-Merino, Jeroen Dijkstra, Carlijn van de Water, Shannon van Lent-van Vliet, Nikki Knijn, Ana-Maria Muşină, Dragos-Viorel Scripcariu, Boryana Popivanova, Mingli Xu, Tomonobu Fujita, Shoichi Hazama, Nobuaki Suzuki, Hiroaki Nagano, Kiyotaka Okuno, Toshihiko Torigoe, Noriyuki Sato, Tomohisa Furuhata, Ichiro Takemasa, Kyogo Itoh, Prabhu S Patel, Hemangini H Vora, Birva Shah, Jayendrakumar B Patel, Kruti N Rajvik, Shashank J Pandya, Shilin N Shukla, Yili Wang, Guanjun Zhang, Yutaka Kawakami, Francesco M Marincola, Paolo A Ascierto, Bernard A Fox, Franck Pagès, and Jérôme Galon
Effects of Radiation on the Tumor Microenvironment., Arta M Monjazeb, Kurt A Schalper, Franz Villarroel-Espindola, Anthony Nguyen, Stephen L Shiao, and Kristina H Young
Effects of Radiation on the Tumor Microenvironment., Arta M Monjazeb, Kurt A Schalper, Franz Villarroel-Espindola, Anthony Nguyen, Stephen L Shiao, and Kristina H Young
Tumor antigen expression and survival of patients with previously treated advanced non-small cell lung cancer (NSCLC) receiving viagenpumatucel-L (HS-110) plus nivolumab., Daniel Morgensztern, Saiama Naheed Waqar, Lyudmila Bazhenova, Lori McDermott, Jeff Hutchins, David H. Taylor, Fred L. Robinson, Alexa K Dowdell, Brian D. Piening, Wael A. Harb, Nathan A. Pennell, and Roger B. Cohen
QP 15 - Biology 07 - Radiation and Immunotherapy, Zachary Scott Morris and Kristina H Young
Effects of YOCAS yoga, cognitive behavioral therapy, and survivorship health education on insomnia: A URCC NCORP Research Base Phase III RCT in 740 cancer survivors., Karen Michelle Mustian, Po-Ju Lin, Eva Culakova, Javier Bautista, Huiwen Xu, Supriya Gupta Mohile, Michelle Christine Janelsins, Luke Joseph Peppone, Amber Kleckner, Ian Kleckner, Kah Poh Loh, Richard Francis Dunne, Nikesha Gilmore, Alison Conlin, Kim Ong Gococo, and Anthony John Jaslowski
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors., Aung Naing, Justin F Gainor, Hans Gelderblom, Patrick M Forde, Marcus O Butler, Chia-Chi Lin, Sunil Sharma, Maria Ochoa de Olza, Andrea Varga, Matthew H Taylor, Jan H M Schellens, Hongqian Wu, Haiying Sun, Antonio P Silva, Jason Faris, Jennifer Mataraza, Scott Cameron, and Todd M Bauer
Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial., Makoto Nishio, Fabrice Barlesi, Howard West, Simon Ball, Rodolfo Bordoni, Manuel Cobo, Pascale Dubray Longeras, Jerome Goldschmidt, Silvia Novello, Francisco Orlandi, Rachel E Sanborn, Zsuzsanna Szalai, Grigoriy Ursol, Diana Mendus, Lijia Wang, Xiaohui Wen, Mark McCleland, Tien Hoang, See Phan, and Mark A Socinski
375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC, M Nishio, F Barlesi, S Ball, R Bordoni, M Cobo, P Dubray-Longeras, J Goldschmidt, S Novello, FJ Orlandi, Rachel E Sanborn, Z Szalai, G Ursol, D Mendus, L Wang, X Wen, M McCleland, T Hoang, S Phan, and M Socinski
375O - Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC, M Nishio (presenter), F Barlesi, S Ball, R Bordoni, M Cobo, P Dubray-Longeras, J Goldschmidt, S Novello, FJ Orlandi, Rachel E Sanborn, Z Szalai, G Ursol, D Mendus, L Wang, X Wen, M McCleland, T Hoang, S Phan, and M Socinski
Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)., Alicia Frances Claire Okines, Elisavet Paplomata, Tanya Wahl, Gail Lynn Shaw Wright, Stephanie Sutherland, Erik Jakobsen, Frances Valdes, Arlene Chan, Amy Sanders Clark, Alison Conlin, Maryam B. Lustberg, Jennifer M. Specht, Timothy J. Pluard, Xiaofu Zhu, Ian E. Krop, Karen A. Gelmon, Dennis J. Slamon, Jorge Ramos, Grace An, and Erika Paige Hamilton
Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide., Ayman J Oweida, Adam C Mueller, Miles Piper, Dallin Milner, Benjamin Van Court, Shilpa Bhatia, Andy Phan, Thomas Bickett, Kimberly Jordan, Theresa Proia, Richard Schulick, Wells A Messersmith, Marco Del Chiaro, Eric Clambey, Michael J. Gough, Jason Williams, Kirk Hansen, Karyn Goodman, and Sana D Karam
Progesterone receptor membrane component 1 promotes the growth of breast cancers by altering the phosphoproteome and augmenting EGFR/PI3K/AKT signalling., Diego A Pedroza, Venkatesh Rajamanickam, Ramadevi Subramani, Alejandra Bencomo, Adriana Galvez, and Rajkumar Lakshmanaswamy
Neoantigen-specific CD4(+) T-cell response is critical for the therapeutic efficacy of cryo-thermal therapy, Peng Peng, Hong-Ming Hu, Ping Liu, and Lisa X Xu
Obesity Drives Delayed Infarct Expansion, Inflammation, and Distinct Gene Networks in a Mouse Stroke Model., Todd C Peterson, Kendra J Lechtenberg, Brian D. Piening, Tawaun A Lucas, Eric Wei, Hassan Chaib, Alexa K Dowdell, Michael Snyder, and Marion S Buckwalter
Enabling Scalable Comprehensive Genomic Profiling from FFPE Samples, Brian D. Piening
Comprehensive Genomic Profiling in Patients with Advanced Cancer in a Large US Healthcare System, Brian D. Piening, Alexa K Dowdell, Roshanthi Weerasinghe, B Bapat, R Roe, Nancy Biery, Shwetha Pindikuri, Sheila Reynolds, David Ball, Mary Campbell, Thomas R. Ward, A Stein, B Schroeder, H Poon, D Eberhard, and Carlo Bifulco
Ageotypes: Distinct Biomolecular Trajectories in Human Aging., Brian D. Piening, Jennifer Lovejoy, and John C Earls
AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report., Era L Pogosova-Agadjanyan, Anna Moseley, Megan Othus, Frederick R Appelbaum, Thomas R Chauncey, I-Ming L Chen, Harry P Erba, John E Godwin, Isaac C Jenkins, Min Fang, Mike Huynh, Kenneth J Kopecky, Alan F List, Jasmine Naru, Jerald P Radich, Emily Stevens, Brooke E Willborg, Cheryl L Willman, Brent L Wood, Qing Zhang, Soheil Meshinchi, and Derek L Stirewalt
Comprehensive Immune Profiling of Medullary Thyroid Cancer., Nikita Pozdeyev, Timothy A Erickson, Lian Zhang, Kim Ellison, Christopher J Rivard, Sharon Sams, Fred R Hirsch, Bryan R Haugen, and Jena D French
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort., Neal E Ready, Patrick A Ott, Matthew D Hellmann, Jon Zugazagoitia, Christine L Hann, Filippo de Braud, Scott J Antonia, Paolo A Ascierto, Victor Moreno, Akin Atmaca, Stefania Salvagni, Matthew H Taylor, Asim Amin, D Ross Camidge, Leora Horn, Emiliano Calvo, Ang Li, Wen Hong Lin, Margaret K Callahan, and David R Spigel
Confirmatory Tissue Sampling in Clinical Stage I Sarcoidosis., Jerome M Reich
Screening for COPD., Jerome M Reich
Response to Grannis FW. Current Controversies in Cardiothoracic Imaging: Overdiagnosis at Lung Cancer Screening-No So Bad After All-Counterpoint., Jerome M Reich and Jong S Kim
Using nitrous acid-modified de Man, Rogosa, and Sharpe medium to selectively isolate and culture lactic acid bacteria from dairy foods., Matthew A Renschler, Asia Wyatt, Nnamdi Anene, Rona Robinson-Hill, Ethan S Pickerill, Nathaniel E Fox, Julie A Griffith, and John L McKillip
Manual Scalp Cooling in Early Stage Breast Cancer: Value of Caretaker Training and Patient-Reported Experience to Optimize Efficacy and Patient Selection, Manaz Rezayee, Nikki Moxon, Staci Mellinger, Amanda Y Seino, Nicole E. Fredich, Tracy L. Kelly, Susan Mulligan, Patrick Rossi, Ijeoma Uche, Walter Urba, Alison Conlin, Janet Ruzich, and David B Page
451 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity, Annah S Rolig, Daniel Rose, Saul Kivimae, Werner Rubas, and William L. Redmond
451 Combining Bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) pairs local innate activation with systemic CD8+ T cell expansion to enhance anti-tumor immunity, Annah S Rolig, Daniel Rose, Saul Kivimae, Werner Rubas, and William L. Redmond
405 CDX1140–01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3), Rachel E Sanborn, Ralph Hauke, Nashat Gabrail, Mark O'Hara, Nina Bhardwaj, Rodolfo Bordoni, Michael Gordon, Danny Khalil, Maen Abdelrahim, Thomas Marron, Thomas Hawthorne, Lawrence Thomas, Tracey Rawls, Diego Alavardo, Laura Vitale, Tibor Keler, and Michael Yellin
405 CDX1140–01, a phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3), Rachel E Sanborn, Ralph Hauke, Nashat Gabrail, Mark O'Hara, Nina Bhardwaj, Rodolfo Bordoni, Michael Gordon, Danny Khalil, Maen Abdelrahim, Thomas Marron, Thomas Hawthorne, Lawrence Thomas, Tracey Rawls, Mark Rogalski, Diego Alvarado, Laura Vitale, Tibor Keler, and Michael Yellin
Concordance of multispectral immunofluorescence (mIF) with programmed death ligand 1 (PD-L1) and stromal tumor infiltrating lymphocyte (sTILs) clinical assays in early-stage breast cancer (BC)., Katherine Sanchez, Shu-Ching Chang, Isaac Kim, Maritza Martel, Yaping Wu, William L. Redmond, Zhaoyu Sun, Dottie Waddell, Deborah R. Laxague, Brady Bernard, Monil Shah, Walter Urba, and David B. Page
Human-engineered Treg-like cells suppress FOXP3-deficient T cells but preserve adaptive immune responses, Yohei Sato, Laura Passerini, Brian D. Piening, Molly Javier Uyeda, Marianne Goodwin, Silvia Gregori, Michael P Snyder, Alice Bertaina, Maria-Grazia Roncarolo, and Rosa Bacchetta
Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study., Alison R. Sehgal, Gerhard Hildebrandt, Nilanjan Ghosh, John E Godwin, Nina D. Wagner-Johnston, Daanish Hoda, Edward J. Licitra, Javier Munoz, Nikolaus S. Trede, Lei Wang, Jerill Thorpe, and Leo I. Gordon
Interim subgroup analysis for response by PD-L1 status of CLASSICAL-Lung, a phase Ib/II study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC., Michael Rahman Shafique, Terrence Lee Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae Electa Pastore, Crystal L. Mallow, Ernest Smith, Andreas Schroder, Kevin M. Chin, Joseph Thaddeus Beck, Megan Ann Baumgart, Ramaswamy Govindan, Nashat Y. Gabrail, Rachel E Sanborn, Alexander I. Spira, Nagashree Seetharamu, Yanyan Lou, Aaron Scott Mansfield, Jonathan Wade Goldman, and Maurice Zauderer
Interim results from a phase Ib/II study of pepinemab in combination with avelumab in advanced NSCLC patients following progression on prior systemic and/or anti-PDx therapies., Michael Rahman Shafique, Terrence Lee Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae Electa Pastore, Crystal L. Mallow, Ernest Smith, Andreas Schroder, Kevin M. Chin, J Thaddeus Beck, Megan Ann Baumgart, Ramaswamy Govindan, Nashat Y. Gabrail, Rachel E Sanborn, Alexander I. Spira, Nagashree Seetharamu, Yan Yan Lou, Aaron Scott Mansfield, Jonathan Wade Goldman, and Maurice Zauderer
1020O A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours, M Sharma, Rachel E Sanborn, GM Cote, JC Bendell, S Kaul, F Chen, A Berezhnoy, P Moore, E Bonvini, BJ Sumrow, and JJ Luke
407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors, Elaine Shum, Adil Daud, Matthew Reilley, Yana Najjar, John Thompson, Joaquina Baranda, R Donald Harvey, Rom Leidner, Anthony Shields, Ezra Cohen, Roger Cohen, Alain Mita, Shubham Pant, Mark Stein, Bartosz Chmielowski, Siwen Hu-Lieskovan, Catherine Fleener, Ying Ding, Sowmya Chollate, Hector Avina, Jolene Shorr, Raphael Clynes, and Barbara Hickingbottom
407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors, Elaine Shum, Adil Daud, Matthew Reilley, Yana Najjar, John Thompson, Joaquina Baranda, R Donald Harvey, Rom Leidner, Anthony Shields, Ezra Cohen, Alain Mita, Shubham Pant, Mark Stein, Bartosz Chmielowski, Siwen Hu-Lieskovan, Catherine Fleener, Ying Ding, Sowmya Chollate, Hector Avina, Jolene Shorr, Raphael Clynes, and Barbara Hickingbottom
Effect of various decontamination procedures on disposable N95 mask integrity and SARS-CoV-2 infectivity, Jeffrey Smith, Haley Hanseler, John Welle, Rogan Rattray, Mary Campbell, Tacy Brotherton, Tarsem Moudgil, Thomas F. Pack, Keith W Wegman, Shawn M. Jensen, Justin Jin, Carlo Bifulco, Scott A. Prahl, Bernard A Fox, and Nicholas L Stucky
Effect of various decontamination procedures on disposable N95 mask integrity and SARS-CoV-2 infectivity., Jeffrey S Smith, Haley Hanseler, John Welle, Rogan Rattray, Mary Campbell, Tacy Brotherton, Tarsem Moudgil, Thomas F Pack, Keith Wegmann, Shawn Jensen, Justin Jin, Carlo B Bifulco, Scott A Prahl, Bernard A Fox, and Nicholas L Stucky
What is the Cost-Effective Treatment for Melanoma Patients with a Positive Sentinel Node?, Hayley Standage, Alyssa R Hersh, Aaron Caughey, Matthew H Taylor, John Vetto, and Dale Han
Response to anti-PD-1 and anti-LAG-3 immune checkpoint blockade (ICB) is associated with induction of pro-inflammatory Tregs, Elizabeth Sturgill, Courtney Mick, Johanna K. Kaufmann, and William L. Redmond
Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors., Vivek Subbiah, Mini I-Nan Hu, Justin F. Gainor, Aaron Scott Mansfield, Guzman Alonso, Matthew H Taylor, Viola Weijia Zhu, Pilar Garrido Lopez, Alessio Amatu, Robert C. Doebele, Philippe Alexandre Cassier, Bhumsuk Keam, Martin H. Schuler, Hui Zhang, Corinne Clifford, Michael Palmer, Jennifer Green, Christopher D. Turner, and Giuseppe Curigliano
560 Alpha-tocopheryloxyacetic acid induces apoptosis of murine rhabdomyosarcoma in vitro while modulating innate and adaptive immune responses in vivo, Fernanda Szewc, Longzhen Song, Sean Rinella, Christopher Dubay, Emmanuel Akporiaye, William L. Redmond, and Christian Capitini
560 Alpha-tocopheryloxyacetic acid induces apoptosis of murine rhabdomyosarcoma in vitro while modulating innate and adaptive immune responses in vivo, Fernanda Szewc, Longzhen Song, Sean Rinella, Christopher Dubay, Emmanuel Akporiaye, William L. Redmond, and Christian Capitini
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation., Janis M Taube, Guray Akturk, Michael Angelo, Elizabeth L Engle, Sacha Gnjatic, Shirley Greenbaum, Noah F Greenwald, Cyrus V Hedvat, Travis J Hollmann, Jonathan Juco, Edwin R Parra, Marlon C Rebelatto, David L Rimm, Jaime Rodriguez-Canales, Kurt A Schalper, Edward C Stack, Cláudia S Ferreira, Konstanty Korski, Ana Lako, Scott J Rodig, Emanuel Schenck, Keith E Steele, Michael J Surace, Michael T Tetzlaff, Katharina von Loga, Ignacio I Wistuba, Carlo Bifulco, and Society for Immunotherapy of Cancer (SITC) Pathology Task Force.
A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies., Matthew H Taylor, Ajjai S Alva, Timothy Larson, Sebastian Szpakowski, Das Purkaystha, Alpesh Amin, Linda Karpiak, and Sarina A Piha-Paul
The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors., Matthew H Taylor, Emmett V Schmidt, Corina Dutcus, Elaine M Pinheiro, Yasuhiro Funahashi, Gregory Lubiniecki, and Drew Rasco
172 Increasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) by gene silencing of PD1 with self-delivering RNAi INTASYL(TM), Colin Thalhofer, Ryan Montler, Melissa Maxwell, Dingxue Yan, James Cardia, Simon Fricker, Jacob Moses, Joshua Rios, Tarsem Moudgil, Bernard A Fox, Nick Morris, Richard Bryan Bell, and Andrew Weinberg
172 Increasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) by gene silencing of PD1 with self-delivering RNAi INTASYL(TM), Colin Thalhofer, Ryan Montler, Melissa Maxwell, Dingxue Yan, James Cardia, Simon Fricker, Jacob Moses, Joshua Rios, Tarsem Moudgil, Bernard A Fox, Nick Morris, Richard Bryan Bell, and Andrew D Weinberg
PROCLAIM-CX-072: Analysis of patients with advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab., Fiona Thistlethwaite, Aung Naing, Marta Gil-Martin, Patricia LoRusso, Manreet Randhawa, Ferry Eskens, Rachel E Sanborn, Nataliya Volodymyrivna Uboha, Daniel C. Cho, Alexander I. Spira, Igor Bondarenko, Elizabeth Ruth Plummer, Javier Garcia-Corbacho, Ivan Victoria, Javier Lavernia, Ignacio Melero, Elisabeth De Vries, William Garner, Hendrik-Tobias Arkenau, and Johanna C. Bendell
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma., John Timmerman, Charles Herbaux, Vincent Ribrag, Andrew D Zelenetz, Roch Houot, Sattva S Neelapu, Theodore Logan, Izidore S Lossos, Walter Urba, Gilles Salles, Radhakrishnan Ramchandren, Caron Jacobson, John Godwin, Cecilia Carpio, Deanne Lathers, Yali Liu, Jaclyn Neely, Satyendra Suryawanshi, Yoshinobu Koguchi, and Ronald Levy
PD-1 and PD-L1 Inhibitors: A Single Center Medication Assistance Program (MAP) Experience, Sarah Tu and Shuntao Cai
Prophylactic Ruxolitinib for Cytokine Release Syndrome in Relapse/Refractory AML Patients Treated with Flotetuzumab., Geoffrey L. Uy, Michael P. Rettig, Stephanie Christ, Ibrahim Aldoss, Michael T. Byrne, Harry P. Erba, Martha L. Arellano, Matthew C. Foster, John E Godwin, Farhad Ravandi, Peter H. Sayre, Anjali S. Advani, Matthew J. Wieduwilt, Ashkan Emadi, Laura C. Michaelis, Patrick J. Stiff, Martin Wermke, Norbert Vey, Patrice Chevalier, Emmanuel Gyan, Christian Recher, Fabio Ciceri, Matteo Giovanni Carrabba, Antonio Curti, Geert Huls, Max S. Topp, Mojca Jongen-Lavrencic, John Muth, Teia Curtis, Mary Beth Collins, Erin Timmeny, Kuo Guo, Jian Zhao, Kathy Tran, Patrick Kaminker, Priyanka Patel, Ouiam Bakkacha, Kenneth Jacobs, Maya Kostova, Jennifer Seiler, Bob Lowenberg, Sergio Rutella, Roland B. Walter, Ezio Bonvini, Jan K. Davidson-Moncada, and John F. DiPersio
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML., Jayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, Sarah E Church, Tressa Hood, Anbarasu Lourdusamy, Michael P Rettig, Ibrahim Aldoss, Anjali S Advani, John E Godwin, Matthew J Wieduwilt, Martha Arellano, John Muth, Tung On Yau, Farhad Ravandi, Kendra Sweet, Heidi Altmann, Gemma A Foulds, Friedrich Stölzel, Jan Moritz Middeke, Marilena Ciciarello, Antonio Curti, Peter J M Valk, Bob Löwenberg, Ivana Gojo, Martin Bornhäuser, John F DiPersio, Jan K Davidson-Moncada, and Sergio Rutella
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML., Jayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, Sarah E Church, Tressa Hood, Anbarasu Lourdusamy, Michael P Rettig, Ibrahim Aldoss, Anjali S Advani, John E Godwin, Matthew J Wieduwilt, Martha Arellano, John Muth, Tung On Yau, Farhad Ravandi, Kendra Sweet, Heidi Altmann, Gemma A Foulds, Friedrich Stölzel, Jan Moritz Middeke, Marilena Ciciarello, Antonio Curti, Peter J M Valk, Bob Löwenberg, Ivana Gojo, Martin Bornhäuser, John F DiPersio, Jan K Davidson-Moncada, and Sergio Rutella
Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia, Jayakumar Vadakekolathu, Tung On Yau, Sarah E. Church, Michael P. Rettig, Ibarhim Aldoss, Geoffrey L. Uy, Norbert Vey, Ashkan Emadi, Peter H. Sayre, Roland B. Walter, Matthew C. Foster, Martha L. Arellano, John E Godwin, Matthew J. Wieduwilt, Michael T. Byrne, Laura C. Michaelis, Patrick J. Stiff, Matteo Giovanni Carrabba, Patrice Chevalier, Emmanuel Gyan, Christian Recher, Anjali S. Advani, Martin Wermke, Harry P. Erba, Fabio Ciceri, Geert Huls, Mojca Jongen-Lavrencic, Farhad Ravandi, Antonio Curti, Max S. Topp, John Muth, Patrick Kaminker, Bob Lowenberg, Ivana Gojo, Leo Luznik, John F. DiPersio, Jan K. Davidson-Moncada, and Sergio Rutella
Transoral robotic surgery and neck dissection for HPV-positive oropharyngeal carcinoma: Importance of nodal count in survival., Chi T Viet, Eric J Dierks, Allen C Cheng, Ashish Patel, Shu-Ching Chang, Marcus Couey, Amber L Watters, Thien Hoang, Hong D Xiao, Marka R Crittenden, Rom Leidner, Steven K Seung, Kristina H Young, and Richard Bryan Bell
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8, Joshua M Walker, Annah S Rolig, Deborah H Charych, Ute Hoch, Melissa Kasiewicz, Daniel Rose, Michael J McNamara, Ian F Hilgart-Martiszus, and William L. Redmond
PANEL DISCUSSION: Vaccine Development for COVID-19, Nathaniel Wang, Andrew J. Geall, and Andrew D Weinberg
Agonist Abs to TNF Receptor Family Members, Andrew D Weinberg
Can OX40 Agonists Increase the Potency of COVID-19 Vaccines?, Andrew D Weinberg
Identifying Tumor-Reactive CD8 TIL in Patients with Solid Malignancies: Clinical Implications, Andrew D Weinberg
Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial., Gregory T Wolf, Siyu Liu, Emily Bellile, Maureen Sartor, Laura Rozek, Dafydd Thomas, Ariane Nguyen, Katie Zarins, Jonathan B McHugh, INSPIRE Trial Clinical Investigators, and R Bryan Bell
Introduction to the Immune System, Anti-tumor Immunity, and Immunotherapy., Kristina H Young
Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity., Lauren Zebertavage, Alejandro F Alice, Marka R Crittenden, and Michael J. Gough
Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP., Yi Zhou, Mingjian Fei, Gu Zhang, Wei-Ching Liang, WeiYu Lin, Yan Wu, Robert Piskol, John Ridgway, Erin McNamara, Haochu Huang, Juan Zhang, Jaehak Oh, Jaina M Patel, Diana Jakubiak, Jeff Lau, Beth Blackwood, Daniel D Bravo, Yongchang Shi, Jianyong Wang, Hong-Ming Hu, Wyne P Lee, Rajiv Jesudason, Dewakar Sangaraju, Zora Modrusan, Keith R Anderson, Søren Warming, Merone Roose-Girma, and Minhong Yan
Submissions from 2019
Current Landscape of Immunotherapy in Breast Cancer: A Review., Sylvia Adams, Margaret E Gatti-Mays, Kevin Kalinsky, Larissa A Korde, Elad Sharon, Laleh Amiri-Kordestani, Harry Bear, Heather L McArthur, Elizabeth Frank, Jane Perlmutter, David B Page, Benjamin Vincent, Jennifer F Hayes, James L Gulley, Jennifer K Litton, Gabriel N Hortobagyi, Stephen Chia, Ian Krop, Julia White, Joseph Sparano, Mary L Disis, and Elizabeth A Mittendorf
Viral Targeting of Non-Muscle-Invasive Bladder Cancer and Priming of Antitumor Immunity Following Intravesical Coxsackievirus A21., Nicola E Annels, David Mansfield, Mehreen Arif, Carmen Ballesteros-Merino, Guy R Simpson, Mick Denyer, Sarbjinder S Sandhu, Alan A Melcher, Kevin J Harrington, Bronwyn Davies, Gough Au, Mark Grose, Izhar Bagwan, Bernard A Fox, Richard Vile, Hugh Mostafid, Darren Shafren, and Hardev S Pandha
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy)., Paolo A Ascierto, Carlo Bifulco, Luigi Buonaguro, Leisha A Emens, Robert L Ferris, Bernard A Fox, Greg M Delgoffe, Jérôme Galon, Cesare Gridelli, Marco Merlano, Paul Nathan, Kunle Odunsi, Hideho Okada, Chrystal M Paulos, Sandro Pignata, Kurt A Schalper, Stefani Spranger, Giampaolo Tortora, Hassane Zarour, Lisa H Butterfield, and Igor Puzanov
Pre-Analytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis., Paolo A Ascierto, Carlo Bifulco, Giuseppe Palmieri, Solange Peters, and Nikoletta Sidiropoulos
Contemporary Techniques in Orbital Reconstruction: A Review of the Literature and Report of a Case Combining Surgical Navigation, Computer-Aided Surgical Simulation, and a Patient-Specific Implant., Iman Azarmehr, Kasper Stokbro, Richard Bryan Bell, and Torben Thygesen
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop., Davide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, Rongze Lu, Karolina Palucka, Josue Samayoa, Stefani Spranger, Sarah Warren, Kwok-Kin Wong, Elad Ziv, Diego Chowell, Lisa M Coussens, Daniel D De Carvalho, David G DeNardo, Jérôme Galon, Howard L Kaufman, Tomas Kirchhoff, Michael T Lotze, Jason J Luke, Andy J Minn, Katerina Politi, Leonard D Shultz, Richard Simon, Vésteinn Thórsson, Joanne B Weidhaas, Maria Libera Ascierto, Paolo Antonio Ascierto, James M Barnes, Valentin Barsan, Praveen K Bommareddy, Adrian Bot, Sarah E Church, Gennaro Ciliberto, Andrea De Maria, Dobrin Draganov, Winson S Ho, Heather M McGee, Anne Monette, Joseph F Murphy, Paola Nisticò, Wungki Park, Maulik Patel, Michael Quigley, Laszlo Radvanyi, Harry Raftopoulos, Nils-Petter Rudqvist, Alexandra Snyder, Randy F Sweis, Sara Valpione, Lisa H Butterfield, Mary L Disis, Bernard A Fox, Alessandra Cesano, and Francesco M Marincola
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop., Davide Bedognetti, Michele Ceccarelli, Lorenzo Galluzzi, Rongze Lu, Karolina Palucka, Josue Samayoa, Stefani Spranger, Sarah Warren, Kwok-Kin Wong, Elad Ziv, Diego Chowell, Lisa M Coussens, Daniel D De Carvalho, David G DeNardo, Jérôme Galon, Howard L Kaufman, Tomas Kirchhoff, Michael T Lotze, Jason J Luke, Andy J Minn, Katerina Politi, Leonard D Shultz, Richard Simon, Vésteinn Thorsson, Joanne B Weidhaas, Maria Libera Ascierto, Paolo Antonio Ascierto, James M Barnes, Valentin Barsan, Praveen K Bommareddy, Adrian Bot, Sarah E Church, Gennaro Ciliberto, Andrea De Maria, Dobrin Draganov, Winson S Ho, Heather M McGee, Anne Monette, Joseph F Murphy, Paola Nisticò, Wungki Park, Maulik Patel, Michael Quigley, Laszlo Radvanyi, Harry Raftopoulos, Nils-Petter Rudqvist, Alexandra Snyder, Randy F Sweis, Sara Valpione, Roberta Zappasodi, Lisa H Butterfield, Mary L Disis, Bernard A Fox, Alessandra Cesano, and Francesco M Marincola
Advances in drug delivery for post-surgical cancer treatment., Lin-Lin Bu, Junjie Yan, Zejun Wang, Huitong Ruan, Qian Chen, Vivienne Gunadhi, Richard Bryan Bell, and Zhen Gu
Simultaneous T Cell Activation and Macrophage Polarization to Promote Potent Tumor Suppression by Iron Oxide-Embedded Large-Pore Mesoporous Organosilica Core-Shell Nanospheres., Lin Chen, Xiaobo Ma, Meng Dang, Heng Dong, Hong-Ming Hu, Xiaodan Su, Wenfei Liu, Qing Wang, Yongbin Mou, and Zhaogang Teng
Tumor-released autophagosomes induces CD4, Yong-Qiang Chen, Peng-Cheng Li, Ning Pan, Rong Gao, Zhi-Fa Wen, Tian-Yu Zhang, Fang Huang, Fang-Yuan Wu, Xi-Long Ou, Jin-Ping Zhang, Xue-Jun Zhu, Hong-Ming Hu, Kang Chen, Yun-Lang Cai, and Li-Xin Wang
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)., Ezra E W Cohen, Richard Bryan Bell, Carlo Bifulco, Barbara Burtness, Maura L Gillison, Kevin J Harrington, Quynh-Thu Le, Nancy Y Lee, Rom Leidner, Rebecca L Lewis, Lisa Licitra, Hisham Mehanna, Loren K Mell, Adam Raben, Andrew G Sikora, Ravindra Uppaluri, Fernanda Whitworth, Dan P Zandberg, and Robert L Ferris
Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM, M Fishman, J P Dutcher, J I Clark, A Alva, G P Miletello, B Curti, Neeraj Agarwal, R Hauke, K M Mahoney, H Moon, J Treisman, S S Tykodi, G Daniels, M A Morse, M K K Wong, H Kaufman, N Gregory, and D F McDermott
Significant differences in outcome between Immunoscore categories in stage I colon cancer patients., J Galon, F Hermitte, B Mlecnik, F Marliot, Carlo Bifulco, A Lugli, I Nagtegaal, A Hartmann, M Van den Eynde, M Roehrl, P Ohashi, E Zavadova, T Torigoe, P Patel, Y Wang, Y Kawakami, F Marincola, P Ascierto, Bernard A Fox, and F Pagès
If we build it they will come: targeting the immune response to breast cancer., Margaret E Gatti-Mays, Justin M Balko, Sofia R Gameiro, Harry D Bear, Sangeetha Prabhakaran, Jami Fukui, Mary L Disis, Rita Nanda, James L Gulley, Kevin Kalinsky, Houssein Abdul Sater, Joseph A Sparano, David Cescon, David B Page, Heather McArthur, Sylvia Adams, and Elizabeth A Mittendorf
Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes., Alena Gros, Eric Tran, Maria R Parkhurst, Sadia Ilyas, Anna Pasetto, Eric M Groh, Paul F Robbins, Rami Yossef, Andrea Garcia-Garijo, Carlos A Fajardo, Todd D Prickett, Li Jia, Jared J Gartner, Satyajit Ray, Lien Ngo, John R Wunderllich, James C Yang, and Steven A Rosenberg
Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma., Andrew J Gunderson, Tomoko Yamazaki, Kayla McCarty, Michaela Phillips, Alejandro F Alice, Shelly Bambina, Lauren Zebertavage, David Friedman, Benjamin Cottam, Pippa Newell, Michael J. Gough, Marka R Crittenden, Pieter Van der Veken, and Kristina H Young
Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models., Peter R Hoffmann, Fukun W Hoffmann, Thomas A Premeaux, Tsuyoshi Fujita, Elisa Soprana, Maddalena Panigada, Glen M Chew, Guilhem Richard, Pooja Hindocha, Mark Menor, Vedbar S Khadka, Youping Deng, Lenny Moise, Lishomwa C Ndhlovu, Antonio Siccardi, Andrew D Weinberg, Anne S De Groot, and Pietro Bertino
